- Home
- EDF vs VIGL Comparison
EDF vs VIGL Comparison
Compare EDF & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- VIGL
- Stock Information
- Founded
- EDF 2010
- VIGL 2020
- Country
- EDF United States
- VIGL United States
- Employees
- EDF N/A
- VIGL N/A
- Industry
- EDF Investment Managers
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- VIGL Health Care
- Exchange
- EDF Nasdaq
- VIGL Nasdaq
- Market Cap
- EDF 148.8M
- VIGL 134.9M
- IPO Year
- EDF N/A
- VIGL 2022
- Fundamental
- Price
- EDF $4.97
- VIGL $7.92
- Analyst Decision
- EDF
- VIGL Buy
- Analyst Count
- EDF 0
- VIGL 7
- Target Price
- EDF N/A
- VIGL $8.00
- AVG Volume (30 Days)
- EDF 160.6K
- VIGL 3.6M
- Earning Date
- EDF 01-01-0001
- VIGL 08-12-2025
- Dividend Yield
- EDF 13.14%
- VIGL N/A
- EPS Growth
- EDF N/A
- VIGL N/A
- EPS
- EDF N/A
- VIGL N/A
- Revenue
- EDF N/A
- VIGL N/A
- Revenue This Year
- EDF N/A
- VIGL N/A
- Revenue Next Year
- EDF N/A
- VIGL N/A
- P/E Ratio
- EDF N/A
- VIGL N/A
- Revenue Growth
- EDF N/A
- VIGL N/A
- 52 Week Low
- EDF $3.51
- VIGL $1.31
- 52 Week High
- EDF $5.50
- VIGL $7.95
- Technical
- Relative Strength Index (RSI)
- EDF 50.98
- VIGL 88.71
- Support Level
- EDF $4.96
- VIGL $7.86
- Resistance Level
- EDF $5.05
- VIGL $7.90
- Average True Range (ATR)
- EDF 0.07
- VIGL 0.03
- MACD
- EDF -0.01
- VIGL -0.18
- Stochastic Oscillator
- EDF 33.00
- VIGL 80.00
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.